---
title: "Zhifei Biological and Merck Sign Revised Agreement to Enhance Strategic Cooperation"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/281519304.md"
description: "Zhifei Biological has signed a revised supply, distribution, and co-promotion agreement with Merck, effective April 2, 2026. This agreement aims to enhance strategic cooperation and market coordination, covering products like the nine-valent HPV vaccine until the end of 2028, with a possible two-year extension. Zhifei will adjust procurement based on market demand, with no base procurement amount specified. Both companies will negotiate procurement plans based on demand forecasts and vaccination rates, confirming details through written orders."
datetime: "2026-04-02T11:55:19.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/281519304.md)
  - [en](https://longbridge.com/en/news/281519304.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/281519304.md)
---

# Zhifei Biological and Merck Sign Revised Agreement to Enhance Strategic Cooperation

Zhifei Biological announced on April 2 that it has signed a revised and restated supply, distribution, and co-promotion agreement with Merck, effective April 2, 2026. According to Jin10, the original agreement will terminate upon the new agreement's activation. The revised agreement aims to deepen strategic cooperation between the two companies, enhance market coordination capabilities, and alleviate operational pressures. The agreement covers products including the nine-valent HPV vaccine, with the collaboration set to continue until the end of 2028, with an option to extend for two additional years. Zhifei Biological will dynamically adjust procurement and supply volumes based on market demand, with regular disclosures on the agreement's execution. The new agreement does not stipulate a base procurement amount for the products. Instead, Zhifei Biological and Merck will negotiate expected procurement and supply plans based on market demand forecasts and actual vaccination rates, with specific procurement details confirmed through written orders from both parties.

### Related Stocks

- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [300122.CN](https://longbridge.com/en/quote/300122.CN.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [MRK.US](https://longbridge.com/en/quote/MRK.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)

## Related News & Research

- [Merck ADC, licensed from China, hits mark in first big global trial](https://longbridge.com/en/news/287075287.md)
- [Allworth Financial LP Grows Stake in Merck & Co., Inc. $MRK](https://longbridge.com/en/news/286522605.md)
- [Health Rounds: Widely used asthma drug may improve performance of cancer immunotherapies](https://longbridge.com/en/news/286957357.md)
- [ZAWYA: Merck marks World Hypertension Day with launch of Hypertension Risk Checker](https://longbridge.com/en/news/286918607.md)
- [15:44 ETIntroducing the Tigerlily Foundation EmpowerHER Peer Navigation Program](https://longbridge.com/en/news/287110224.md)